159 related articles for article (PubMed ID: 28736944)
21. Effect of acute reduction of free fatty acids by acipimox on growth hormone-releasing hormone-induced GH secretion in type 1 diabetic patients.
Alvarez P; Isidro L; Peinó R; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
Clin Endocrinol (Oxf); 2003 Oct; 59(4):431-6. PubMed ID: 14510904
[TBL] [Abstract][Full Text] [Related]
22. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
Santomauro AT; Boden G; Silva ME; Rocha DM; Santos RF; Ursich MJ; Strassmann PG; Wajchenberg BL
Diabetes; 1999 Sep; 48(9):1836-41. PubMed ID: 10480616
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
J Clin Endocrinol Metab; 2001 Dec; 86(12):5813-8. PubMed ID: 11739444
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution.
Hadigan C; Rabe J; Meininger G; Aliabadi N; Breu J; Grinspoon S
Am J Clin Nutr; 2003 Feb; 77(2):490-4. PubMed ID: 12540412
[TBL] [Abstract][Full Text] [Related]
25. The diagnosis of GH deficiency in obese patients: a reappraisal with GHRH plus arginine testing after pharmacological blockade of lipolysis.
Scacchi M; Orsini F; Cattaneo A; Grasso A; Filippini B; Pecori Giraldi F; Fatti LM; Moro M; Cavagnini F
Eur J Endocrinol; 2010 Aug; 163(2):201-6. PubMed ID: 20460421
[TBL] [Abstract][Full Text] [Related]
26. Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men.
Van Dam PS; Smid HE; de Vries WR; Niesink M; Bolscher E; Waasdorp EJ; Dieguez C; Casanueva FF; Koppeschaar HP
J Clin Endocrinol Metab; 2000 Dec; 85(12):4706-11. PubMed ID: 11134132
[TBL] [Abstract][Full Text] [Related]
27. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of lipolysis by nicotinic acid and by acipimox.
Fuccella LM; Goldaniga G; Lovisolo P; Maggi E; Musatti L; Mandelli V; Sirtori CR
Clin Pharmacol Ther; 1980 Dec; 28(6):790-5. PubMed ID: 7438693
[TBL] [Abstract][Full Text] [Related]
29. Effects of GH replacement therapy in adults on serum levels of leptin and ghrelin: the role of lipolysis.
Vestergaard ET; Hansen TK; Nielsen S; Moller N; Christiansen JS; Jorgensen JO
Eur J Endocrinol; 2005 Oct; 153(4):545-9. PubMed ID: 16189176
[TBL] [Abstract][Full Text] [Related]
30. Acute pharmacologic blockade of lipolysis normalizes nocturnal growth hormone levels and pulsatility in obese subjects.
Andreotti AC; Lanzi R; Manzoni MF; Caumo A; Moreschi A; Pontiroli AE
Metabolism; 1994 Oct; 43(10):1207-13. PubMed ID: 7934970
[TBL] [Abstract][Full Text] [Related]
31. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans.
Nuutila P; Knuuti MJ; Raitakari M; Ruotsalainen U; Teräs M; Voipio-Pulkki LM; Haaparanta M; Solin O; Wegelius U; Yki-Järvinen H
Am J Physiol; 1994 Dec; 267(6 Pt 1):E941-6. PubMed ID: 7810638
[TBL] [Abstract][Full Text] [Related]
32. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects.
Malmström R; Packard CJ; Caslake M; Bedford D; Stewart P; Yki-Järvinen H; Shepherd J; Taskinen MR
Diabetes; 1998 May; 47(5):779-87. PubMed ID: 9588450
[TBL] [Abstract][Full Text] [Related]
33. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
Cusi K; Kashyap S; Gastaldelli A; Bajaj M; Cersosimo E
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1775-81. PubMed ID: 17299078
[TBL] [Abstract][Full Text] [Related]
34. Growth hormone upregulates ANGPTL4 mRNA and suppresses lipoprotein lipase via fatty acids: Randomized experiments in human individuals.
Hjelholt AJ; Søndergaard E; Pedersen SB; Møller N; Jessen N; Jørgensen JOL
Metabolism; 2020 Apr; 105():154188. PubMed ID: 32084431
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of lipolysis stimulates peripheral glucose uptake but has no effect on endogenous glucose production in HIV lipodystrophy.
Lindegaard B; Frøsig C; Petersen AM; Plomgaard P; Ditlevsen S; Mittendorfer B; Van Hall G; Wojtaszewski JF; Pedersen BK
Diabetes; 2007 Aug; 56(8):2070-7. PubMed ID: 17601993
[TBL] [Abstract][Full Text] [Related]
36. Leptin levels in humans are acutely suppressed by isoproterenol despite acipimox-induced inhibition of lipolysis, but not by free fatty acids.
Stumvoll M; Fritsche A; Tschritter O; Lehmann R; Wahl HG; Renn W; Häring H
Metabolism; 2000 Mar; 49(3):335-9. PubMed ID: 10726911
[TBL] [Abstract][Full Text] [Related]
37. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.
Paolisso G; Tagliamonte MR; Rizzo MR; Gualdiero P; Saccomanno F; Gambardella A; Giugliano D; D'Onofrio F; Howard BV
Diabetologia; 1998 Oct; 41(10):1127-32. PubMed ID: 9794097
[TBL] [Abstract][Full Text] [Related]
38. Lowering plasma free fatty acids with Acipimox mimics the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker diabetic fatty rats.
Blachère JC; Pérusse F; Bukowiecki LJ
Metabolism; 2001 Aug; 50(8):945-51. PubMed ID: 11474483
[TBL] [Abstract][Full Text] [Related]
39. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
Fulcher GR; Catalano C; Walker M; Farrer M; Thow J; Whately-Smith CR; Alberti KG
Diabet Med; 1992 Dec; 9(10):908-14. PubMed ID: 1478035
[TBL] [Abstract][Full Text] [Related]
40. Plasma free fatty acids and serum insulin in subjects feeding at 12-hour intervals; effects of methionyl growth hormone and of acipimox, an inhibitor of lipolysis.
Pontiroli AE; Lanzi R; Monzani M; Musatti L; Guglielmone C; Pozza G
J Endocrinol Invest; 1992 Feb; 15(2):85-91. PubMed ID: 1569294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
